Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ARQ 171: Phase I data

In an open-label, dose-escalation, U.S. Phase I trial (ARQ 171-101), doses

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE